Hims & Hers (HIMS) Stock Analysis 2026: The Telehealth Disruptor

Last Updated: March 2026 | By WealthIQ Editorial

Hims & Hers built a $2B+ revenue business by making prescription healthcare feel like an e-commerce transaction. The model is working — but the path to sustainable profitability is still the central question most analysts are wrestling with.

What Is Hims & Hers Health?

Hims & Hers Health (NYSE: HIMS) is a telehealth company that offers prescription medications, wellness products, and consultations through a direct-to-consumer digital platform. Founded in 2017 and taken public via SPAC in January 2021, it initially focused on men’s health categories — hair loss (finasteride), erectile dysfunction (sildenafil), and skincare. The company later expanded into women’s health, mental health, and most significantly, weight loss.

The business model is subscription-based: customers pay a monthly fee for ongoing access to licensed providers and prescription medications shipped directly to their doors. This model sidesteps the traditional pharmacy and in-person doctor visit friction, and it resonates strongly with a demographic that values convenience and privacy.

The GLP-1 Opportunity — and the Risk

The defining event in Hims & Hers’ recent history is its entry into the GLP-1 weight loss market. GLP-1 drugs like semaglutide (branded as Ozempic, Wegovy) became blockbuster products in 2022–2024, but were plagued by severe supply shortages. When a drug is on the FDA’s official shortage list, compounding pharmacies are legally permitted to produce and sell it at lower prices.

Hims & Hers seized this opportunity in 2024, launching compounded semaglutide at a fraction of the branded price ($199/month vs. $1,000+ for Wegovy). The response was enormous: it drove a significant portion of the company’s accelerating revenue growth and subscriber additions in 2024.

The risk: the FDA removed semaglutide from the shortage list in early 2025, which legally requires compounding pharmacies to stop production. Hims & Hers challenged the ruling and continued selling through early 2025, but ultimately faced regulatory pressure to wind down the compounded semaglutide program. The company has pivoted to emphasizing personalized compounded formulations (which may have a longer regulatory runway) and exploring branded GLP-1 partnerships.

This regulatory overhang is the central risk factor for HIMS shareholders in 2025–2026.

Financial Performance: 2022–2025

2024E and 2025E are analyst estimates as of early 2026. Revenue figures rounded. Past performance not predictive of future results.

Core Business: Beyond GLP-1

It’s important not to reduce Hims & Hers to a GLP-1 story. The company’s original verticals remain strong:

• Hair loss: Finasteride and minoxidil subscriptions remain a core revenue contributor with high retention rates.
• Sexual health: Sildenafil and tadalafil (generic Viagra/Cialis) are popular, high-margin subscription products.
• Mental health: Psychiatric consultations and SSRI/SNRI prescriptions, a growing segment with high LTV.
• Women’s health: The “Hers” brand covers birth control, menopause management, and skincare.

These verticals collectively represent a durable subscription business with high gross margins and improving unit economics. Even if GLP-1 revenue compresses materially, the core business has grown substantially since 2021.

Bull Case for HIMS

• Category leadership: Hims & Hers has built one of the strongest consumer health brands in telehealth, with high unaided awareness among 18–45 year olds.
• Gross margin strength: 78–80% gross margins indicate strong pricing power and operational efficiency — rare in healthcare.
• GLP-1 pivot to personalized formulations: Personalized compounded medications (containing semaglutide plus other active agents) may continue to be legally permitted even after the shortage listing is resolved, providing a regulatory-compliant revenue stream.
• Branded GLP-1 partnerships: The company has signaled interest in becoming a distribution partner or affiliate for branded GLP-1 manufacturers, which could replace compounded revenue with branded revenue at lower margins but with no regulatory risk.
• Valuation reset: After losing over 60% from its 2024 peak, HIMS trades at a more reasonable 3–4x forward revenue, pricing in significant GLP-1 headwinds.

Bear Case for HIMS

• GLP-1 revenue cliff: If compounded semaglutide is fully shut down, the company could lose an estimated 30–40% of its 2024 revenue run-rate within a few quarters. The 2025 guidance range reflects this wide uncertainty.
• Subscriber churn: Customers who subscribed specifically for GLP-1 drugs and lose that access may cancel entirely rather than convert to other services.
• Regulatory overhang: The FDA relationship is now adversarial. Future regulatory actions in other categories (e.g., mental health prescribing standards, compounding pharmacy oversight) could create additional headwinds.
• Competition: Ro, Noom, WeightWatchers, Amazon Clinic, and traditional healthcare systems are all competing for the digital health subscriber. Customer acquisition costs (CAC) are rising industrywide.
• SPAC legacy: HIMS went public via SPAC in 2021 at elevated valuations. Some institutional investors remain structurally underweight SPAC-origin companies.

How to Invest in HIMS

HIMS is a publicly traded stock on the New York Stock Exchange. You can buy it through any brokerage account. Given the high volatility and binary risk around FDA developments, position sizing is particularly important.

• Robinhood — Commission-free, fractional shares available, easy mobile interface for active monitoring.
• Webull — Commission-free with more advanced charting and options capabilities for experienced investors.

Given the regulatory uncertainty, HIMS is better suited to investors with high risk tolerance and a conviction-based thesis, not as a core portfolio holding. A position of 1–3% of a portfolio is a reasonable exposure level for those who believe in the long-term telehealth thesis while acknowledging the near-term GLP-1 risk.

Metric	2022	2023	2024E	2025E
Revenue	$527M	$872M	~$1.35B	~$1.6–2.0B (wide range)
Subscribers	~736K	~1.1M	~1.5M+	1.5–2.0M (GLP-1 dependent)
Gross Margin	~77%	~80%	~78–80%	~75–79% (mix shift)
P/S Ratio	~3x	~4x	~5–6x (at peak)	~3–4x (post-FDA sell-off)

Bottom Line

Hims & Hers is one of the most genuinely disruptive companies in U.S. healthcare — it has demonstrated that consumers will pay for convenient, private, subscription-based access to medical care, and it has built real revenue and brand equity to prove it. The GLP-1 opportunity made it a high-flier in 2024, and the FDA complications turned it into a volatile, controversial stock in 2025. For investors who can stomach the uncertainty and believe the core business will outlast the regulatory noise, HIMS at current valuations offers an interesting risk/reward proposition. For conservative investors, the binary regulatory risk makes it a pass.

Disclosure: WealthIQ may earn a commission if you open an account through links on this page. This is not investment advice. All data accurate as of March 2026.